Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Withdrawal in Immune Mediated Enteropathies
NCT03866538Phase 4Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2019
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of EPI-EE in Refractory celiac disease type 1 (RCD1), common variable immunodeficiency (CVID), autoimmune enteropathy (AIE), Collagenous sprue (CS), sponsored by Mayo Clinic. Started Sep 2019; status: terminated.
02
Drugs
EPI-EE
03
Conditions
Refractory celiac disease type 1 (RCD1)common variable immunodeficiency (CVID)autoimmune enteropathy (AIE)Collagenous sprue (CS)
Beyond the preview
Go deeper on NCT03866538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866538.